Market Snapshot
S&P Futures
4,132.75
Dow Futures
32,794
Nasdaq Futures
13,103.75
Rubius Therapeutics, Inc. (RUBY) stock rallied over 2.97% intraday to trade at $0.7929 a share on NASDAQ. The stock opened with a gain of 8.62% at $0.85 and touched an intraday high of $0.86, rising 2.97% against the last close of $0.77. The stock went to a low of $0.785 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-08-08 | $0.85 | $0.86 | $0.785 | $0.793 | 437,171 |
2022-08-05 | $0.73 | $0.797 | $0.72 | $0.77 | 411,900 |
2022-08-04 | $0.75 | $0.767 | $0.725 | $0.73 | 351,400 |
2022-08-03 | $0.687 | $0.88 | $0.687 | $0.74 | 1,599,700 |
2022-08-02 | $0.66 | $0.714 | $0.65 | $0.684 | 349,600 |
2022-08-01 | $0.713 | $0.77 | $0.652 | $0.652 | 618,200 |
2022-07-29 | $0.7 | $0.713 | $0.69 | $0.702 | 303,300 |
2022-07-28 | $0.758 | $0.758 | $0.705 | $0.705 | 237,600 |
2022-07-27 | $0.701 | $0.755 | $0.701 | $0.73 | 184,500 |
2022-07-26 | $0.73 | $0.743 | $0.7 | $0.7 | 232,300 |
Employees-
Beta2.59
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics, Inc. (NASDAQ: RUBY) stock price is $0.7929 as of the last check on Monday, August 8. During the trading session, RUBY stock reached the peak price of $0.86 while $0.785 was the lowest point it dropped to.
The NASDAQ listed RUBY is part of Biotechnology industry that operates in the broader Health Care sector. Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases.
Ms. Elhan Webb C.F.A.
VP of Investor Relations
Mr. David R. Epstein B.Sc., M.B.A.
Exec. Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.
CEO, Pres & Director
Mr. Jose I. Carmona
CFO, Principal Accounting Officer & Treasurer
RUBY stock traded closed the last session at $0.793, which is $0.02290000000000003 or 2.9740259740259782% lower than its previous close of $0.77. RUBY's current trading price is 21.98% lower than its 52-week high of $24.84 where as its distance from 52-week low of 0.65% is -96.81%.
Number of RUBY employees currently stands at -. RUBY operates from 399 Binney Street, Suite 300, Cambridge, MA 02139, United States.
Official Webiste of $RUBY is: https://www.rubiustx.com
RUBY could be contacted at RUBY operates from 399 Binney Street, Suite 300, Cambridge, MA 02139, United States, or at phone #617 679 9600 and can also be accessed through its website.
RUBY stock volume for the day was 441,317 shares while in the previous session number of RUBY shares traded was 437,171 . The average number of RUBY shares traded daily for last 3 months was 814.07 Thousands.
The percentage change in RUBY stock occurred in the recent session was 2.9740259740259782% while the dollar amount for the price change in RUBY stock was $0.02290000000000003.
In the recent session, the day high for RUBY stock was $0.86 while the low for RUBY stock touched on the day was $0.785.
The market value of RUBY currently stands at 67.96 Million with its latest stock price at $0.7929 and 90.15 Million of its shares outstanding.